Cutting-edge biotherapeutics and advanced delivery strategies for the treatment of metabolic dysfunction-associated steatotic liver disease spectrum

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 433 - 456

Published: Feb. 11, 2025

Language: Английский

Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk

Biomolecules, Journal Year: 2025, Volume and Issue: 15(2), P. 163 - 163

Published: Jan. 22, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is correlated with an increased cardiovascular risk, independent of other traditional risk factors. The mechanisms underlying this pathogenic link are complex yet remain incompletely elucidated. Among these, the most significant visceral adiposity, low-grade inflammation and oxidative stress, endothelial dysfunction, prothrombotic status, insulin resistance, dyslipidemia postprandial hyperlipemia, gut dysbiosis, genetic mutations. Cardiovascular diseases leading cause death in patients MASLD. These have incidence coronary artery disease, carotid structural functional cardiac abnormalities, valvulopathies, as well arrhythmias conduction disorders. In review, we present latest data on association between MASLD focusing that explain correlation these two pathologies. Given high rates morbidity mortality among MASLD, consider it imperative to raise awareness risks associated condition within general population. Further research essential clarify linked This understanding may facilitate identification new diagnostic prognostic biomarkers for patients, novel therapeutic targets.

Language: Английский

GPNMB regulates the differentiation and transformation of monocyte-derived macrophages during MASLD

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 154, P. 114554 - 114554

Published: April 6, 2025

Language: Английский